Recap: Iovance Biotherapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings, missing estimated earnings by 2.22% with an EPS of $-0.46 versus an estimate of $-0.45. However, revenue was up $469 thousand from the same period last year. Last quarter, the company beat EPS estimates which led to a 6.44% increase in the share price the next day.
November 07, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Iovance Biotherapeutics missed Q3 earnings estimates but reported increased revenue. Last quarter's beat led to a share price increase.
Iovance Biotherapeutics missed its Q3 earnings estimates, which could negatively impact the stock price. However, the company reported increased revenue compared to the same period last year, which is a positive sign. Additionally, the company's stock price increased after beating estimates last quarter, suggesting that the market reacts strongly to its earnings reports.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100